An assessment of statin safety by hepatologists.
The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.
Cohen
David E
DE
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. dcohen@partners.org
Anania
Frank A
FA
Chalasani
Naga
N
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D000075202:Contraindications; D019317:Evidence-Based Medicine; D005234:Fatty Liver / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D008099:Liver / Q000201:enzymology; D017093:Liver Failure / Q000139:chemically induced*; D008111:Liver Function Tests; D016031:Liver Transplantation
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase